Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Chinese Patent Office
Julphar
Colorcon
Dow
Cerilliant
Federal Trade Commission
Harvard Business School
Merck

Generated: November 15, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BUMETANIDE

« Back to Dashboard

Clinical Trials for Bumetanide

Trial ID Title Status Sponsor Phase Summary
NCT00372762 Bumetanide Versus Furosemide in Heart Failure Withdrawn University of Western Ontario, Canada Phase 3 Patients with NYHA FC II-III heart failure will be randomized in a cross-over fashion to 8 weeks of bumetanide versus furosemide therapy (equipotent dose), to test whether bumetanide therapy has a superior effect on insulin resistance compared to furosemide. Patients will be subject to a frequently sampled intravenous glucose tolerance test (FSIGT) with minimal model (MINMOD) analysis to assess insulin resistance and to a 6-minute walk test (6MWT) to assess functional capacity; patient recruitment and retention success, as well as medication adherence, will also be assessed.
NCT00372762 Bumetanide Versus Furosemide in Heart Failure Withdrawn Lawson Health Research Institute Phase 3 Patients with NYHA FC II-III heart failure will be randomized in a cross-over fashion to 8 weeks of bumetanide versus furosemide therapy (equipotent dose), to test whether bumetanide therapy has a superior effect on insulin resistance compared to furosemide. Patients will be subject to a frequently sampled intravenous glucose tolerance test (FSIGT) with minimal model (MINMOD) analysis to assess insulin resistance and to a 6-minute walk test (6MWT) to assess functional capacity; patient recruitment and retention success, as well as medication adherence, will also be assessed.
NCT00830531 Pilot Study of Bumetanide for Newborn Seizures Recruiting Charles H. Hood Foundation Phase 1 The main goal of the study is to obtain pharmacokinetic and safety data of bumetanide in newborns with refractory seizures. The overall hypothesis is that bumetanide, added to conventional antiepileptic (antiseizure) medications, will be a safe and well tolerated medication, compared with conventional antiepileptic drugs alone.
NCT00830531 Pilot Study of Bumetanide for Newborn Seizures Recruiting Citizens United for Research in Epilepsy Phase 1 The main goal of the study is to obtain pharmacokinetic and safety data of bumetanide in newborns with refractory seizures. The overall hypothesis is that bumetanide, added to conventional antiepileptic (antiseizure) medications, will be a safe and well tolerated medication, compared with conventional antiepileptic drugs alone.
NCT00830531 Pilot Study of Bumetanide for Newborn Seizures Recruiting Harvard Catalyst- Harvard Clinical and Translational Science Center Phase 1 The main goal of the study is to obtain pharmacokinetic and safety data of bumetanide in newborns with refractory seizures. The overall hypothesis is that bumetanide, added to conventional antiepileptic (antiseizure) medications, will be a safe and well tolerated medication, compared with conventional antiepileptic drugs alone.
NCT00830531 Pilot Study of Bumetanide for Newborn Seizures Recruiting National Institute of Neurological Disorders and Stroke (NINDS) Phase 1 The main goal of the study is to obtain pharmacokinetic and safety data of bumetanide in newborns with refractory seizures. The overall hypothesis is that bumetanide, added to conventional antiepileptic (antiseizure) medications, will be a safe and well tolerated medication, compared with conventional antiepileptic drugs alone.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Bumetanide

Condition Name

Condition Name for Bumetanide
Intervention Trials
Acute Decompensated Heart Failure 3
Autistics Children 1
Hypokalemic Periodic Paralysis 1
Autistic Disorder 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Bumetanide
Intervention Trials
Heart Failure 5
Autistic Disorder 3
Seizures 2
Renal Insufficiency 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Bumetanide

Trials by Country

Trials by Country for Bumetanide
Location Trials
United States 7
United Kingdom 2
France 2
Netherlands 1
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Bumetanide
Location Trials
New York 1
Michigan 1
New Mexico 1
North Carolina 1
Ohio 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Bumetanide

Clinical Trial Phase

Clinical Trial Phase for Bumetanide
Clinical Trial Phase Trials
Phase 4 1
Phase 3 2
Phase 2 3
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Bumetanide
Clinical Trial Phase Trials
Recruiting 5
Not yet recruiting 5
Completed 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Bumetanide

Sponsor Name

Sponsor Name for Bumetanide
Sponsor Trials
Great Ormond Street Hospital for Children NHS Foundation Trust 1
Bristol-Myers Squibb 1
scPharmaceuticals, Inc. 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Bumetanide
Sponsor Trials
Other 30
Industry 6
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Queensland Health
Mallinckrodt
US Army
Deloitte
Cipla
UBS
Daiichi Sankyo
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.